The following is a summary of “Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year ...

In the years since targeted treatments for CLL were introduced, their use in the second line has increased, but chemotherapy ...

Data from the same showed that treatment with Calquence in combination with chemoimmunotherapy significantly delayed disease progression and showed a trend to improve survival in patients with ...

Most people within these stages, once they start treatment, get chemoimmunotherapy. That’s chemotherapy plus monoclonal antibodies (antibodies made in a lab). You usually get chemotherapy for ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

“Patients who undergo autologous stem cell transplantation in addition to initial chemoimmunotherapy and subsequent ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Current recommendations suggest treating elderly CLL patients with good physical status and low burden of comorbidities with chemoimmunotherapy, consisting of non-fludarabine-based regimens.

Data from the ECHO trial showed CALQUENCE plus chemoimmunotherapy significantly delayed disease progression and showed a trend to improved survival in patients with this currently incurable blood ...

Calquence plus bendamustine and rituximab reduced disease progression or death by 27% versus standard chemoimmunotherapy. Median progression-free survival increased to 66.4 months with Calquence ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...